-
摘要: 目的 基于生物信息学研究Lutheran血型基底细胞黏附分子基因(basal cell adhesion molecule，BCAM)在肾透明细胞癌(kidney renal clear cell carcinoma，KIRC)中的表达及临床意义。方法 从UCSC Xena数据门户(
https://xenabrowser.net/ )下载经统一标准化的泛癌数据集：TCGA Pan-Cancer(PANCAN，n=10 535，G=60 499)以及临床随访数据。使用Sangerbox、GEPIA和UALCAN等数据库进行综合分析，评估Lutheran血型BCAM基因在KIRC中的表达水平及其在临床预后中的潜在价值。结果 Lutheran血型BCAM基因在不同肿瘤存在着表达差异，BCAM在14种肿瘤中观察到了显著上调(P < 0.05)，在12种肿瘤中观察到了显著下调(P < 0.05)，其中BCAM在KIRC组织中mRNA表达水平显著低于正常组织(6.59±0.94 vs 8.48±1.69，P < 0.05)。在KIRC中BCAM低表达与高级别的肿瘤分期、分级、淋巴结转移和远处转移等不良临床特征密切相关(P < 0.05)。BAP1基因在KIRC中具有广泛的突变(突变率34.7%)，与高表达组比较BCAM在低表达组的突变频率显著高于高表达组。生存分析表明，BCAM表达水平与KIRC总生存期呈显著正相关(P < 0.05)。基于单因素Cox和多因素Cox回归结果分析低表达BCAM是KIRC预后危险因素。结论 Lutheran血型BCAM基因在多数KIRC中表达水平较低，与KIRC的发生、发展以及不良预后相关，有望作为KIRC诊疗、预后评判的重要指标。-
关键词:
- Lutheran血型 /
- 基底细胞黏附分子基因 /
- 肾透明细胞癌 /
- 生物信息学
Abstract: Objective To study the expression of Lutheran blood group basal cell adhesion molecule(BCAM) gene in Kidney renal clear cell carcinoma(KIRC) based on bioinformatics KIRC expression and its clinical significance.Methods The unified and standardized Pan-Cancer dataset TCGA Pan-cancer(PANCAN, n=10 535, G=60 499) and clinical follow-up data were downloaded from the UCSC Xena data portal(https://xenabrowser.net/ ). Sangerbox, GEPIA and UALCAN databases were used for comprehensive analysis to evaluate the expression level of Lutheran BCAM gene in KIRC and its potential value in clinical prognosis.Results Lutheran blood type BCAM gene expression was different in different tumors. BCAM was significantly up-regulated in 14 tumors(P < 0.05), and significantly down-regulated in 12 tumors(P < 0.05). The expression of BCAM mRNA in KIRC tissues was significantly lower than that in normal tissues(6.59±0.94 vs 8.48±1.69, P < 0.05). The low expression of BCAM in KIRC was closely related to high tumor stage, grade lymph node metastasis and distant metastasis(P < 0.05). The BAP1 gene was widely mutated in KIRC with a mutation rate of 34.7%. The mutation frequency of BCAM in KIRC with low BAP1 expression was significantly higher than that in KIRC with high BAP1 expression. Survival analysis showed that the expression level of BCAM was positively correlated with the overall survival of KIRC(P < 0.05). Based on univariate Cox and multivariate Cox regression analysis, low expression of BCAM was a risk factor for the prognosis of KIRC.Conclusion Lutheran BCAM gene was low expressed in most KIRC, which might be related to the occurrence, development and poor prognosis of KIRC. It might be used as an important indicator for the diagnosis and treatment of KIRC. -
-
[1] Li MY, Li L, Zheng JY, et al. Liquid biopsy at the frontier in renal cell carcinoma: recent analysis of techniques and clinical application[J]. Mol Cancer, 2023, 22(1): 37. doi: 10.1186/s12943-023-01745-7
[2] Fan B, Niu YF, Ren ZT, et al. Long noncoding RNA MMP2-AS1 contributes to progression of renal cell carcinoma by modulating miR-34c-5p/MMP2 axis[J]. J Oncol, 2022, 2022: 7346460.
[3] Li L, Zhu CY, Xu SY, et al. PUS1 is a novel biomarker for evaluating malignancy of human renal cell carcinoma[J]. Aging, 2023, 15(11): 5215-5227.
[4] 来翀, 孙庆荣, 来茂德, 等. 第5版WHO肾细胞癌分型的临床应用及思考[J]. 中华病理学杂志, 2023, 52(4): 328-332.
[5] WHO Classification of Tumours Editorial Board. WHO classification of tumours. Urinary and male genital tumours[M]. 5th ed. Lyon: IARC Press, 2022.
[6] Tronik-Le Roux D, Sautreuil M, Bentriou M, et al. Comprehensive landscape of immune-checkpoints uncovered in clear cell renal cell carcinoma reveals new and emerging therapeutic targets[J]. Cancer Immunol Immunother, 2020, 69(7): 1237-1252. doi: 10.1007/s00262-020-02530-x
[7] Dell'Atti L, Bianchi N, Aguiari G. New therapeutic interventions for kidney carcinoma: looking to the future[J]. Cancers, 2022, 14(15): 3616. doi: 10.3390/cancers14153616
[8] Łukasz Trzciniecki M, Bursiewicz W, Trzciniecka M, et al. The role of intraoperative transesophageal echocardiography in the management of renal cell carcinoma with atrial Thrombus-case report[J]. J Ultrason, 2023, 23(92): 28-31. doi: 10.15557/JoU.2023.0005
[9] Kesireddy M, Correa A, Correa R, et al. A pedunculated skin lesion in a case of clear cell renal carcinoma[J]. Cureus, 2019, 11(6): e5021.
[10] He X, Tian F, Guo F, et al. Circulating exosomal mRNA signatures for the early diagnosis of clear cell renal cell carcinoma[J]. BMC Med, 2022, 20(1): 270. doi: 10.1186/s12916-022-02467-1
[11] 邓瑜颖, 李树中, 李中华, 等. 红细胞血型Lutheran抗原研究进展[J]. 临床血液学杂志, 2021, 34(8): 593-599. doi: 10.13201/j.issn.1004-2806.2021.08.017
[12] 魏华, 杨世明, 富文达, 等. Lutheran血型抗原rs7026、rs3669位点中TT基因型增加人恶性肿瘤易感性[J]. 细胞与分子免疫学杂志, 2022, 38(10): 925-930.
[13] Global Cardiovascular Risk Consortium, Magnussen C, Ojeda FM, et al. Global effect of modifiable risk factors on cardiovascular disease and mortality[J]. N Engl J Med, 2023, 389(14): 1273-1285. doi: 10.1056/NEJMoa2206916
[14] Vasan SK, Rostgaard K, Majeed A, et al. ABO blood group and risk of thromboembolic and arterial disease: a study of 1.5 million blood donors[J]. Circulation, 2016, 133(15): 1449-1457;discussion 1457. doi: 10.1161/CIRCULATIONAHA.115.017563
[15] Dahlén T, Clements M, Zhao JC, et al. An agnostic study of associations between ABO and RhD blood group and phenome-wide disease risk[J]. Elife, 2021, 10: e65658. doi: 10.7554/eLife.65658
[16] Li S, Schooling CM. A phenome-wide association study of ABO blood groups[J]. BMC Med, 2020, 18(1): 334. doi: 10.1186/s12916-020-01795-4
[17] Group SCG, Ellinghaus D, Degenhardt F, et al. Genomewide association study of severe covid-19 with respiratory failure[J]. N Engl J Med, 2020, 383(16): 1522-1534. doi: 10.1056/NEJMoa2020283
[18] Bruun-Rasmussen P, Hanefeld Dziegiel M, Banasik K, et al. Associations of ABO and Rhesus D blood groups with phenome-wide disease incidence: a 41-year retrospective cohort study of 482, 914 patients[J]. Elife, 2023, 12: e83116. doi: 10.7554/eLife.83116
[19] Yu Q, Fu WH, Fu YT, et al. BNIP3 as a potential biomarker for the identification of prognosis and diagnosis in solid tumours[J]. Mol Cancer, 2023, 22(1): 143. doi: 10.1186/s12943-023-01808-9
[20] 周仁龙, 钟靖, 唐丹丹. Kidd血型相关SLC14A1基因在肾透明细胞癌中的表达及临床意义[J]. 临床输血与检验, 2024, 26(1): 92-100.
[21] 周仁龙, 黄国清, 李凌波, 等. 血型CD59基因在胰腺癌中的表达及临床意义[J]. 临床输血与检验, 2024, 26(1): 101-109.
[22] Chandrashekar DS, Karthikeyan SK, Korla PK, et al. UALCAN: an update to the integrated cancer data analysis platform[J]. Neoplasia, 2022, 25: 18-27. doi: 10.1016/j.neo.2022.01.001
[23] Xue W, Jian WG, Meng YY, et al. Knockdown of SETD2 promotes erastin-induced ferroptosis in ccRCC[J]. Cell Death Dis, 2023, 14(8): 539. doi: 10.1038/s41419-023-06057-8
[24] 于凯聪, 叶子, 汪晓东, 等. ABO血型在结直肠癌中的意义的研究进展[J]. 中国普外基础与临床杂志, 2023, 30(7): 877-881.
[25] 胥兴丽. 胃癌与ABO血型及幽门螺旋杆菌感染相关性分析[D]. 青岛: 青岛大学, 2020.
[26] 黄彬亮, 谢钊敏, 王丹, 等. 广东潮汕地区恶性肿瘤与ABO血型的相关性分析[J]. 中国输血杂志, 2023, 36(3): 254-257.
[27] Singh A, Purohit BM. ABO blood groups and its association with oral cancer, oral potentially malignant disorders and oral submucous fibrosis-A systematic review and meta-analysis[J]. Asian Pac J Cancer Prev, 2021, 22(6): 1703-1712.
[28] Huang JY, Wang RW, Gao YT, et al. ABO blood type and the risk of cancer-Findings from the Shanghai Cohort Study[J]. PLoS One, 2017, 12(9): e0184295.
[29] Lai JZ, Fu YJ, Tian SR, et al. Zebularine elevates STING expression and enhances cGAMP cancer immunotherapy in mice[J]. Mol Ther, 2021, 29(5): 1758-1771.
[30] Fu JH, Zhou CC, Mu HQ, et al. CD18 inhibits progression of kidney cancer by down-regulating Treg cell levels[J]. Eur Rev Med Pharmacol Sci, 2019, 23(7): 2750-2755.
[31] Montalvo-Casimiro M, González-Barrios R, Meraz-Rodriguez MA, et al. Epidrug repurposing: discovering new faces of old acquaintances in cancer therapy[J]. Front Oncol, 2020, 10: 605386. doi: 10.3389/fonc.2020.605386
[32] Jonasch E, Walker CL, Rathmell WK. Clear cell renal cell carcinoma ontogeny and mechanisms of lethality[J]. Nat Rev Nephrol, 2021, 17(4): 245-261. doi: 10.1038/s41581-020-00359-2
[33] Han NN, Li X, Wang YP, et al. Increased tumor-infiltrating plasmacytoid dendritic cells promote cancer cell proliferation and invasion via TNF-α/NF-κB/CXCR-4 pathway in oral squamous cell carcinoma[J]. J Cancer, 2021, 12(10): 3045-3056.
[34] Wang ZJ, Zhang SC, Zheng CC, et al. CTHRC1 is a potential prognostic biomarker and correlated with macrophage infiltration in breast cancer[J]. Int J Gen Med, 2022, 15: 5701-5713.
[35] Jin J, Xie SS, Sun Q, et al. Upregulation of BCAM and its sense lncRNA BAN are associated with gastric cancer metastasis and poor prognosis[J]. Mol Oncol, 2020, 14(4): 829-845.
-
下载:
图(7)
计量
- 文章访问数: 955
- PDF下载数: 198
- 施引文献: 0